Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 101

1.

Vaginal microbicide gel for delivery of IQP-0528, a pyrimidinedione analog with a dual mechanism of action against HIV-1.

Mahalingam A, Simmons AP, Ugaonkar SR, Watson KM, Dezzutti CS, Rohan LC, Buckheit RW Jr, Kiser PF.

Antimicrob Agents Chemother. 2011 Apr;55(4):1650-60. doi: 10.1128/AAC.01368-10. Epub 2011 Jan 18.

2.

Vaginal film drug delivery of the pyrimidinedione IQP-0528 for the prevention of HIV infection.

Ham AS, Rohan LC, Boczar A, Yang L, W Buckheit K, Buckheit RW Jr.

Pharm Res. 2012 Jul;29(7):1897-907. doi: 10.1007/s11095-012-0715-7. Epub 2012 Mar 6.

3.

Safety and efficacy of tenofovir/IQP-0528 combination gels - a dual compartment microbicide for HIV-1 prevention.

Dezzutti CS, Shetler C, Mahalingam A, Ugaonkar SR, Gwozdz G, Buckheit KW, Buckheit RW Jr.

Antiviral Res. 2012 Nov;96(2):221-5. doi: 10.1016/j.antiviral.2012.08.004. Epub 2012 Aug 23.

4.

Safe and sustained vaginal delivery of pyrimidinedione HIV-1 inhibitors from polyurethane intravaginal rings.

Johnson TJ, Srinivasan P, Albright TH, Watson-Buckheit K, Rabe L, Martin A, Pau CP, Hendry RM, Otten R, McNicholl J, Buckheit R Jr, Smith J, Kiser PF.

Antimicrob Agents Chemother. 2012 Mar;56(3):1291-9. doi: 10.1128/AAC.05721-11. Epub 2011 Dec 12.

5.

Development of a combination microbicide gel formulation containing IQP-0528 and tenofovir for the prevention of HIV infection.

Ham AS, Ugaonkar SR, Shi L, Buckheit KW, Lakougna H, Nagaraja U, Gwozdz G, Goldman L, Kiser PF, Buckheit RW Jr.

J Pharm Sci. 2012 Apr;101(4):1423-35. doi: 10.1002/jps.23026. Epub 2012 Jan 6.

PMID:
22227864
6.

The rational design and development of a dual chamber vaginal/rectal microbicide gel formulation for HIV prevention.

Ham AS, Nugent ST, Peters JJ, Katz DF, Shelter CM, Dezzutti CS, Boczar AD, Buckheit KW, Buckheit RW Jr.

Antiviral Res. 2015 Aug;120:153-64. doi: 10.1016/j.antiviral.2015.06.010. Epub 2015 Jun 17.

7.

Development and in vitro evaluation of a vaginal microbicide gel formulation for UAMC01398, a novel diaryltriazine NNRTI against HIV-1.

Grammen C, Ariën KK, Venkatraj M, Joossens J, Van der Veken P, Heeres J, Lewi PJ, Haenen S, Augustyns K, Vanham G, Augustijns P, Brouwers J.

Antiviral Res. 2014 Jan;101:113-21. doi: 10.1016/j.antiviral.2013.11.005. Epub 2013 Nov 20.

PMID:
24269474
8.

Development and characterization of a solid dispersion film for the vaginal application of the anti-HIV microbicide UAMC01398.

Grammen C, Van den Mooter G, Appeltans B, Michiels J, Crucitti T, Ariën KK, Augustyns K, Augustijns P, Brouwers J.

Int J Pharm. 2014 Nov 20;475(1-2):238-44. doi: 10.1016/j.ijpharm.2014.08.054. Epub 2014 Aug 28.

PMID:
25175729
9.

Vaginal deployment and tenofovir delivery by microbicide gels.

Gao Y, Yuan A, Chuchuen O, Ham A, Yang KH, Katz DF.

Drug Deliv Transl Res. 2015 Jun;5(3):279-94. doi: 10.1007/s13346-015-0227-1.

10.

Non-aqueous silicone elastomer gels as a vaginal microbicide delivery system for the HIV-1 entry inhibitor maraviroc.

Forbes CJ, Lowry D, Geer L, Veazey RS, Shattock RJ, Klasse PJ, Mitchnick M, Goldman L, Doyle LA, Muldoon BC, Woolfson AD, Moore JP, Malcolm RK.

J Control Release. 2011 Dec 10;156(2):161-9. doi: 10.1016/j.jconrel.2011.08.006. Epub 2011 Aug 12.

11.

Durable protection from vaginal simian-human immunodeficiency virus infection in macaques by tenofovir gel and its relationship to drug levels in tissue.

Dobard C, Sharma S, Martin A, Pau CP, Holder A, Kuklenyik Z, Lipscomb J, Hanson DL, Smith J, Novembre FJ, García-Lerma JG, Heneine W.

J Virol. 2012 Jan;86(2):718-25. doi: 10.1128/JVI.05842-11. Epub 2011 Nov 9.

12.

Formulation development and evaluation of innovative two-polymer (SR-2P) bioadhesive vaginal gel.

Podaralla S, Alt C, Shankar GN.

AAPS PharmSciTech. 2014 Aug;15(4):928-38. doi: 10.1208/s12249-014-0124-9. Epub 2014 Apr 30.

13.

Modified silicone elastomer vaginal gels for sustained release of antiretroviral HIV microbicides.

Forbes CJ, McCoy CF, Murphy DJ, Woolfson AD, Moore JP, Evans A, Shattock RJ, Malcolm RK.

J Pharm Sci. 2014 May;103(5):1422-32. doi: 10.1002/jps.23913. Epub 2014 Mar 1.

14.

An Intravaginal Ring for the Simultaneous Delivery of an HIV-1 Maturation Inhibitor and Reverse-Transcriptase Inhibitor for Prophylaxis of HIV Transmission.

Ugaonkar SR, Clark JT, English LB, Johnson TJ, Buckheit KW, Bahde RJ, Appella DH, Buckheit RW Jr, Kiser PF.

J Pharm Sci. 2015 Oct;104(10):3426-39. doi: 10.1002/jps.24551. Epub 2015 Jul 6.

15.

In vitro and ex vivo evaluations on transdermal delivery of the HIV inhibitor IQP-0410.

Ham AS, Lustig W, Yang L, Boczar A, Buckheit KW, Buckheit RW Jr.

PLoS One. 2013 Sep 18;8(9):e75306. doi: 10.1371/journal.pone.0075306. eCollection 2013.

16.

Semi-solid gels function as physical barriers to human immunodeficiency virus transport in vitro.

Lai BE, Geonnotti AR, Desoto MG, Montefiori DC, Katz DF.

Antiviral Res. 2010 Nov;88(2):143-51. doi: 10.1016/j.antiviral.2010.08.006. Epub 2010 Aug 13.

17.

Reformulated tenofovir gel for use as a dual compartment microbicide.

Dezzutti CS, Rohan LC, Wang L, Uranker K, Shetler C, Cost M, Lynam JD, Friend D.

J Antimicrob Chemother. 2012 Sep;67(9):2139-42. doi: 10.1093/jac/dks173. Epub 2012 May 11.

18.

Development and in vitro evaluation of chloroquine gels as microbicides against HIV-1 infection.

Brouwers J, Vermeire K, Schols D, Augustijns P.

Virology. 2008 Sep 1;378(2):306-10. doi: 10.1016/j.virol.2008.06.005. Epub 2008 Jul 7.

19.

Formulation of the microbicide INP0341 for in vivo protection against a vaginal challenge by Chlamydia trachomatis.

Pedersen C, Slepenkin A, Andersson SB, Fagerberg JH, Bergström CA, Peterson EM.

PLoS One. 2014 Oct 30;9(10):e110918. doi: 10.1371/journal.pone.0110918. eCollection 2014.

20.

Preclinical studies on thiocarboxanilide UC-781 as a virucidal agent.

Balzarini J, Naesens L, Verbeken E, Laga M, Van Damme L, Parniak M, Van Mellaert L, Anné J, De Clercq E.

AIDS. 1998 Jul 9;12(10):1129-38.

PMID:
9677161

Supplemental Content

Support Center